Johnson & Johnson presents new IMAAVY data, shares tracked on the NYSE

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-26, 20:22.

Johnson & Johnson (US4781601046) today reported new clinical data for its antibody IMAAVY (nipocalimab-aahu) in generalized myasthenia gravis from the European Academy of Neurology 2026 Congress, according to a Business Wire release distributed via PR Newswire. The healthcare group, whose stock trades on the New York Stock Exchange, emphasized sustained disease control signals that could further underpin its immunology franchise.

New EAN 2026 data on nipocalimab

The company stated that the latest IMAAVY data were presented at the European Academy of Neurology (EAN) 2026 Congress and focused on patients with generalized myasthenia gravis, a chronic autoimmune neuromuscular disease. In its update, Johnson & Johnson highlighted measures of sustained disease control, building on earlier findings from the program. The PR Newswire communication outlines the updated efficacy and safety profile.

Nipocalimab targets the neonatal Fc receptor (FcRn), a mechanism that can reduce pathogenic IgG antibodies implicated in autoimmune conditions. Johnson & Johnson has been positioning the asset as part of a broader strategy in autoantibody-driven diseases, complementing other immunology treatments in its portfolio and supporting its pharmaceuticals growth ambitions.

How analysts frame Johnson & Johnson

On the equity side, Johnson & Johnson remains a widely followed large-cap healthcare name, with consensus data from several market platforms showing a mix of Buy and Hold recommendations and an average 12-month price target in the low triple-digit US-dollar range, according to recent analyst compilations. Large houses such as Goldman Sachs, JPMorgan and Bank of America regularly update their views on the stock, reflecting its role as a defensive component in diversified portfolios and its diversified exposure to pharmaceuticals, medical devices and consumer health.

Market commentary from U.S. financial portals describes Johnson & Johnson shares as influenced both by pipeline milestones like the IMAAVY data and by broader healthcare sector sentiment, alongside peers such as Pfizer, Merck & Co. and Abbott Laboratories. For many analysts, the balance between litigation developments, innovation output and capital returns remains central to how they frame risk and valuation for the stock.

What the company sells

Johnson & Johnson generates revenue mainly from pharmaceuticals, medical devices and consumer health products, including well-known brands such as Tylenol pain relief. Its research-driven drug portfolio, now featuring candidates like nipocalimab, remains a key earnings driver alongside established device lines.

Where the stock trades today

Johnson & Johnson shares last traded on the New York Stock Exchange at around the low 150s US dollars, according to recent intraday data from major financial portals on 2026-06-26. The company ranks among the larger constituents of major U.S. healthcare and blue-chip indices.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.